DUBLIN, July 22, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/phctfk/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering.
Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022.
Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022.
A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments.
Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics.
The pipeline review of glioblastoma treatment market has been segmented as below:
Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
- Bevacizumab (Avastin)
- Temozolomide (Temodar and Temodal and Temcad)
- Carmustine (BiCNU)
Global Pipeline Review of Glioblastoma Treatment- Overview- Late Stage (Phase III)- - DCVax- - Rindopepimut (CDX-110)- - Others- Early Stage (Phase I, II and Pre clinical)- - ABT-414- - MM-398- - ARC-100- - AV0113- - Cotara- - Crenolanib- - SGT-53- - Endostatin- - ANG1005- Others
- AbbVie, Inc.- Activartis GmbH- Agenus Inc.- Arog Pharmaceuticals, Inc.- Bristol-Myers Squibb Company- CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)- Cavion LLC- Celldex Therapeutics Inc.- Cortice Biosciences Inc.- Eisai Co., Ltd.- Exelixis Inc.- F. Hoffmann-La Roche Ltd.- Merrimack Pharmaceuticals, Inc.- OncoSynergy- Peregrine Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/phctfk/glioblastoma
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets